Market Overview:
The global pneumonia vaccine market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of pneumonia, meningitis, and sepsis across the globe. In addition, rising awareness about preventive measures against these diseases is also contributing to the growth of this market. The pneumococcal conjugate vaccine (PCV13) segment is expected to account for the largest share of the global pneumonia vaccine market in 2018. This segment is anticipated to grow at a CAGR of 11% during the forecast period. The large share of this segment can be attributed to its high efficacy in preventing pneumococcal infections caused by Streptococcus pneumoniae bacteria and growing demand for PCV13 vaccines globally.
Product Definition:
A pneumococcal vaccine is a vaccine used to protect against the bacteria Streptococcus pneumoniae. The vaccine is made from killed S. pneumoniae bacteria. It is given by injection into a muscle, usually in the arm or thigh.
Pneumococcal Conjugate Vaccine (PCV13):
Pneumococcal Conjugate Vaccine (PCV13) is a vaccine developed by Merck & Co. It works by preventing bacteria from entering the body through the respiratory tract. The conjugate technology used in this vaccine involves two antigens, namely, Neisseria meningitides and serogroup 13 Streptococcus pneumoniae.
Pneumococcal Polysaccharide Vaccine (PPSV23):
Pneumococcal polysaccharide vaccine (PPSV23) is a type of pneumococcal conjugate vaccine. It protects against seven types of Streptococcus pneumoniae bacteria, which are responsible for causing invasive disease in humans. PPSV23 was approved by the U.
Application Insights:
Based on the application, the global pneumonia vaccine market is segmented into meningitis, sepsis, and pneumonia. The meningitis segment dominated the overall market in terms of revenue share in 2017 owing to high incidence rates of bacterial meningitis across regions. Bacterial meningitis is a severe form of infection that causes inflammation and blood flow from the skull to the brain which can lead to permanent disability or death if not treated properly. According to WHO, there were approximately 10 million cases of bacterial meningitis globally in 2016 which resulted in about 60 thousand deaths annually.
The sepsis segment is expected to witness lucrative growth over forecast period due largelyto increasing number of severe infections caused by multi-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) & Escherichia coli among others globally including China, India & U.S.
Regional Analysis:
North America dominated the global market in 2017. The rising incidence of pneumococcal disease and the implementation of a number of initiatives by government bodies to boost immunization rates are some factors responsible for its largest share. For instance, in December 2016, CDC along with state health departments and other partners launched an initiative to increase pneumococcal vaccination from 55% coverage rate achieved in 2014 to 70% by 2020.
Asia Pacific is expected to be the fastest-growing region over the forecast period owing to increasing immunization programs against pneumonia and meningitis as well as rising awareness about these vaccines among healthcare professionals & patients coupled with supportive government initiatives & spending on research & development activities for new vaccine technologies. In addition, growing penetration of private sector companies into developing markets is also anticipated favorably impact growth during this period. For instance, Novartis AG has entered into a collaboration with GlaxoSmithKline plc’s GSK Biologicals Ltd.
Growth Factors:
- Increasing incidence of pneumonia across the globe
- Growing awareness about the benefits of vaccination against pneumonia
- Rising demand for pneumococcal vaccines due to increasing prevalence of pneumococcal diseases
- Technological advancements in vaccine development and manufacturing processes
- Growing investments by pharmaceutical companies in research and development of new pneumococcal vaccines
Scope Of The Report
Report Attributes
Report Details
Report Title
Pneumonia Vaccine Market Research Report
By Type
Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23)
By Application
Pneumonia, Meningitis, Sepsis
By Companies
Pfizer Inc., Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Johnson & Johnson, Astellas Pharma Inc., Astrazeneca Plc., CSL Limited, Emergent Biosolutions
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Pneumonia Vaccine Market Report Segments:
The global Pneumonia Vaccine market is segmented on the basis of:
Types
Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pneumonia, Meningitis, Sepsis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer Inc.
- Glaxosmithkline Plc.
- Merck & Co., Inc.
- Sanofi Pasteur
- Serum Institute of India Pvt. Ltd.
- Johnson & Johnson
- Astellas Pharma Inc.
- Astrazeneca Plc.
- CSL Limited
- Emergent Biosolutions
Highlights of The Pneumonia Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Pneumococcal Conjugate Vaccine (PCV13)
- Pneumococcal Polysaccharide Vaccine (PPSV23)
- By Application:
- Pneumonia
- Meningitis
- Sepsis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pneumonia Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pneumonia vaccine is a vaccine that helps protect people from pneumonia. It is made up of pieces of the bacteria that cause pneumonia, and it helps the body fight off infection by these bacteria.
Some of the major players in the pneumonia vaccine market are Pfizer Inc., Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Johnson & Johnson, Astellas Pharma Inc., Astrazeneca Plc., CSL Limited, Emergent Biosolutions.
The pneumonia vaccine market is expected to register a CAGR of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pneumonia Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pneumonia Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pneumonia Vaccine Market - Supply Chain
4.5. Global Pneumonia Vaccine Market Forecast
4.5.1. Pneumonia Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pneumonia Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pneumonia Vaccine Market Absolute $ Opportunity
5. Global Pneumonia Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pneumonia Vaccine Market Size and Volume Forecast by Type
5.3.1. Pneumococcal Conjugate Vaccine (PCV13)
5.3.2. Pneumococcal Polysaccharide Vaccine (PPSV23)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pneumonia Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pneumonia Vaccine Market Size and Volume Forecast by Application
6.3.1. Pneumonia
6.3.2. Meningitis
6.3.3. Sepsis
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pneumonia Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pneumonia Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pneumonia Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pneumonia Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pneumonia Vaccine Demand Share Forecast, 2019-2026
9. North America Pneumonia Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pneumonia Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pneumonia Vaccine Market Size and Volume Forecast by Application
9.4.1. Pneumonia
9.4.2. Meningitis
9.4.3. Sepsis
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pneumonia Vaccine Market Size and Volume Forecast by Type
9.7.1. Pneumococcal Conjugate Vaccine (PCV13)
9.7.2. Pneumococcal Polysaccharide Vaccine (PPSV23)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pneumonia Vaccine Demand Share Forecast, 2019-2026
10. Latin America Pneumonia Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pneumonia Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pneumonia Vaccine Market Size and Volume Forecast by Application
10.4.1. Pneumonia
10.4.2. Meningitis
10.4.3. Sepsis
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pneumonia Vaccine Market Size and Volume Forecast by Type
10.7.1. Pneumococcal Conjugate Vaccine (PCV13)
10.7.2. Pneumococcal Polysaccharide Vaccine (PPSV23)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pneumonia Vaccine Demand Share Forecast, 2019-2026
11. Europe Pneumonia Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pneumonia Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pneumonia Vaccine Market Size and Volume Forecast by Application
11.4.1. Pneumonia
11.4.2. Meningitis
11.4.3. Sepsis
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pneumonia Vaccine Market Size and Volume Forecast by Type
11.7.1. Pneumococcal Conjugate Vaccine (PCV13)
11.7.2. Pneumococcal Polysaccharide Vaccine (PPSV23)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attrctiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pneumonia Vaccine Demand Share, 2019-2026
12. Asia Pacific Pneumonia Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pneumonia Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pneumonia Vaccine Market Size and Volume Forecast by Application
12.4.1. Pneumonia
12.4.2. Meningitis
12.4.3. Sepsis
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pneumonia Vaccine Market Size and Volume Forecast by Type
12.7.1. Pneumococcal Conjugate Vaccine (PCV13)
12.7.2. Pneumococcal Polysaccharide Vaccine (PPSV23)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pneumonia Vaccine Demand Share, 2019-2026
13. Middle East & Africa Pneumonia Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pneumonia Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pneumonia Vaccine Market Size and Volume Forecast by Application
13.4.1. Pneumonia
13.4.2. Meningitis
13.4.3. Sepsis
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pneumonia Vaccine Market Size and Volume Forecast by Type
13.7.1. Pneumococcal Conjugate Vaccine (PCV13)
13.7.2. Pneumococcal Polysaccharide Vaccine (PPSV23)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pneumonia Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pneumonia Vaccine Market: Market Share Analysis
14.2. Pneumonia Vaccine Distributors and Customers
14.3. Pneumonia Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Glaxosmithkline Plc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck & Co., Inc.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sanofi Pasteur
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Serum Institute of India Pvt. Ltd.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Johnson & Johnson
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Astellas Pharma Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Astrazeneca Plc.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. CSL Limited
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Emergent Biosolutions
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
